Develop new screening methods and treatments for newborns with potentially fatal or disabling disorders identified through newborn screening, focusing on high priority genetic conditions with potential for future screening.
Funder: National Institutes of Health
Due Dates: February 16, 2027 (New) | March 16, 2027 (Resubmission/revision) | June 16, 2027 (New) | July 16, 2027 (Resubmission/revision) | October 16, 2027 (New) | November 16, 2027 (Resubmission/revision)
Funding Amounts: Grants.gov lists a $200,000 award ceiling; NIH specifies up to $275,000 in direct costs over two years, with $200,000 maximum annually.
Summary: Supports exploratory research on innovative newborn screening approaches and treatments for screenable, potentially fatal or disabling conditions.
Key Information: Clinical trials are optional; preliminary data are not required for R21 applications.
The NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) supports exploratory and developmental research to improve newborn screening and early treatment. Projects may address conditions already included in newborn screening panels or “high priority” genetic conditions not currently recommended for screening, where infants would significantly benefit from early identification and treatment.
This R21 opportunity supports novel ideas, new applications of existing technologies or therapies, and pilot data generation for larger studies. Interests span basic, behavioral, translational, and clinical research: screening assays and algorithms, alternative specimen types, preclinical therapy development, treatment trials, comparative effectiveness, disease modifiers, access to care, and embedded ethical, legal, and social research. The goal is to close gaps in reliable screening and effective early intervention that limit screening’s benefits.